Long-Acting Buprenorphine Medications as a Novel Pharmacological Option in Opioid Dependence

被引：1
|
作者：
Soyka, Michael [1 ,2 ]
机构：
[1] Med Pk Chiemseeblick, Rasthausstr 25, D-83233 Bernau Felden, Germany
[2] Psychiat Univ Klin LMU Munchen, Munich, Germany
来源：
SUCHTTHERAPIE | 2020年 / 21卷 / 01期
关键词：
opioid dependence; maintenance treatment; buprenorphine; depot; implant; SUSTAINED-RELEASE FORMULATION; FOLLOW-UP; METHADONE-MAINTENANCE; USE DISORDER; HEROIN; ADDICTION; RETENTION; MORTALITY; BLOCKADE; RBP-6000;
D O I：
10.1055/a-1064-6188
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Opioid maintenance treatment with oral methadone or sublingual buprenorphine is an established first-line treatment in opioid dependence. Both drugs must be taken daily (methadone) or at least every second day (buprenorphine). Apart from the novel subcutaneous weekly and monthly depot formulations CAM 2038 (Buvidal (R)) 2 other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade (TM)) and a 6-month buprenorphine implant (Probuphine (TM)). Clininical findings of these three medications are given and possible clinical indications are discussed.
引用
收藏
页码：13 / 18
页数：6
相关论文
共 50 条
  • [41] Barriers to utilizing long-acting injectable antipsychotic medications
    Getzen, Hayley
    Beasley, Marie
    D'Mello, Dale A.
    ANNALS OF CLINICAL PSYCHIATRY, 2014, 26 (01) : 33 - 38
  • [42] Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations
    Coe, Marion A.
    Lofwall, Michelle R.
    Walsh, Sharon L.
    JOURNAL OF ADDICTION MEDICINE, 2019, 13 (02) : 93 - 103
  • [43] COMMUNITY IMPACTS OF THE SCALE UP OF LONG-ACTING INJECTION BUPRENORPHINE
    McLeod, Leah
    Lord, Sarah
    DRUG AND ALCOHOL REVIEW, 2021, 40 : S19 - S19
  • [44] Outcomes of Treatment With Long-Acting Buprenorphine Injection in Individuals With Opioid Use Disorder Attending a Rehabilitation Center in the UAE
    Tolba, Hossameldin
    Foad, Wael
    Ameri, Abdulrazaq
    Abdullah, Saeed
    El Hayek, Samer
    BJPSYCH OPEN, 2024, 10 : S186 - S187
  • [45] Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health
    Martin, Emily
    Maher, Hayley
    McKeon, Gemma
    Patterson, Sue
    Blake, Julie
    Chen, Kai Yang
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 139
  • [46] Outcomes of Treatment With Long-Acting Buprenorphine Injection in Individuals With Opioid Use Disorder Attending a Rehabilitation Center in the UAE
    Tolba, Hossameldin
    Foad, Wael
    Ameri, Abdulrazaq
    Abdullah, Saeed
    El Hayek, Samer
    BJPSYCH OPEN, 2024, 10 : S186 - S187
  • [47] Long-Acting Injectable Antipsychotics: An Underutilized Treatment Option
    Heres, Stephan
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (11) : 1263 - 1265
  • [48] Long-acting medications for the treatment of hyperkinetic disorders -: A systematic review and European treatment guidelines.: Part 2:: A quantitative evaluation of long-acting medications
    Banaschewski, Tobias
    Coghill, David
    Santosh, Parmala
    Zuddas, Alessandro
    Asherson, Philip
    Buitelaar, Jan
    Danckaerta, Marina
    Doepfner, Manfred
    Faraone, Stephen V.
    Rothenberger, Aribert
    Sergeant, Joseph
    Steinhausen, Hans-Christoph
    Sonuga-Barke, Edmund J. -S.
    Taylor, Eric
    ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, 2008, 36 (02): : 97 - 107
  • [49] Long-acting naltrexone injection for opioid use disorder
    Kang, Seema
    LANCET PSYCHIATRY, 2018, 5 (12): : 967 - 967
  • [50] Long-acting opioid initiation in US nursing homes
    Hunnicutt, Jacob N.
    Hume, Anne L.
    Ulbricht, Christine M.
    Tjia, Jennifer
    Lapane, Kate L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (01) : 31 - 38
12345